ReviewSpringer seminars in immunopathology2006
Regulatory T cells in human autoimmune diseases.
Review in Springer seminars in immunopathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 73 citations in OpenAlex.
- The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis.Electronic physician · 2016Article
- Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment.Immunobiology · 2015Article
- Late-onset of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome (IPEX) with intractable diarrhea.Italian journal of pediatrics · 2014Article
- T helper cell polarization in healthy people: implications for cardiovascular disease.Journal of cardiovascular translational research · 2013Review
- Functional defect in regulatory T cells in myasthenia gravis.Annals of the New York Academy of Sciences · 2012Review
- Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.Clinical immunology (Orlando, Fla.) · 2012Article
- Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells.Muscle & nerve · 2012Article
- Is multiple sclerosis an autoimmune disease?Autoimmune diseases · 2012Article
- GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis.Journal of neuroimmunology · 2011Article
- Cross-talk between cd1d-restricted nkt cells and γδ cells in t regulatory cell response.Virology journal · 2011Review
- T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.Cellular immunology · 2011Article
- Frequency of Treg cells is reduced in CVID patients with autoimmunity and splenomegaly and is associated with expanded CD21lo B lymphocytes.Journal of clinical immunology · 2010Article
- Development of thymically derived natural regulatory T cells.Annals of the New York Academy of Sciences · 2010Review
- Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome.Clinical immunology (Orlando, Fla.) · 2009Article
- Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis.Endocrine · 2009Article
- IL-12R beta 2 promotes the development of CD4+CD25+ regulatory T cells.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- The neoplastically transformed (CD30hi) Marek's disease lymphoma cell phenotype most closely resembles T-regulatory cells.Cancer immunology, immunotherapy : CII · 2008Article
- Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies.Journal of clinical immunology · 2008Review
- IPEX as a result of mutations in FOXP3.Clinical & developmental immunology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the most simplistic terms, immune tolerance can be envisioned as a balance with autoreactive cells that arise naturally in all individuals on one side and regulatory mechanisms designed to counter those autoreactive processes on the other. A tilt of the balance toward the autoreactive side, either by increasing the number or function of autoreactive cells or by diminishing regulatory mechanisms, is manifested as autoimmunity. In contrast, tilting of the balance toward increased regulation could conceivably cause immunodeficiency. Regulatory T cells (T(REG)), and particularly the naturally arising CD4(+)CD25(+) subset of T(REG) cells, provide a substantial component of the autoimmune counterbalance. The identification of forkhead box P3 (FOXP3) as a critical determinant of CD4(+)CD25(+) T(REG) development and function has provided new opportunities and generated expanded interest in studying the delicate balance between autoimmunity and regulatory mechanisms in human autoimmune diseases. Identification of both human and mouse syndromes in which FOXP3 is mutated, and consequently CD4(+)CD25(+) T(REG) cells are absent, has led to a rapid accumulation of knowledge regarding T(REG) development and function over the past 5 years. The recent development of antibody reagents to specifically identify CD4(+)CD25(+) T(REG) cells by their FOXP3 expression has provided new tools to identify these elusive cells and investigate their role in human disease. This review will focus on the current state of knowledge regarding the role of T(REG) in human autoimmune diseases and on specific human immunodeficiencies that provide interesting models of autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.